Press Releases July 30, 2026 04:05 PM

CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026

CapsoVision to announce Q2 2026 financial results and host conference call on August 13, 2026

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CV

CapsoVision, a US-based commercial-stage medical technology company specializing in AI-enabled capsule endoscopy, will release its Q2 2026 financial results after market close on August 13, 2026, followed by a conference call and webcast to discuss the results and corporate updates.

CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
CV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CapsoVision focuses on innovative AI-enabled capsule endoscopy products for gastrointestinal disease screening.
  • The company’s flagship wire-free CapsoCam Plus provides high-resolution visualization and supports cloud-based or direct video retrieval.
  • Upcoming Q2 2026 earnings release and conference call aims to update investors on financial performance and business progress impacting the medical technology sector.

SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 9178774. The live and archived webcast of the conference call can be found on the Events page in the Investor Relations section of CapsoVision’s website.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com

Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231


Risks

  • Dependence on successful commercialization and market adoption of novel medical devices in a competitive healthcare technology sector.
  • Potential regulatory and reimbursement challenges affecting medical device sales and healthcare market dynamics.
  • Uncertainty regarding the financial results performance and the impact of corporate developments on future growth prospects.

More from Press Releases

Critical Metals Corp. Merger with European Lithium Advances to Shareholder Vote Following Court Ruling Sep 15, 2026 XTEND Expands Global Footprint with New Site in Mexico as Mexico Allocates $17.5 Billion to Defense and Security in 2026¹ Sep 15, 2026 Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics Sep 15, 2026 Safe Harbor to Address Banking and Capital Access for Colorado Cannabis Operators at IgniteIt Market Spotlight 2026 Sep 15, 2026 PolyPid Announces Participation in Upcoming Fall Investor Conferences Sep 15, 2026